Aurobindo Pharma Limited (NSE:AUROPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 712.88B |
| Revenue (ttm) | 325.14B |
| Net Income (ttm) | 34.22B |
| Shares Out | 580.80M |
| EPS (ttm) | 58.93 |
| PE Ratio | 20.83 |
| Forward PE | 17.87 |
| Dividend | 8.00 (0.66%) |
| Ex-Dividend Date | Aug 8, 2025 |
| Volume | 667,410 |
| Average Volume | 1,424,697 |
| Open | 1,227.40 |
| Previous Close | 1,227.40 |
| Day's Range | 1,222.60 - 1,239.00 |
| 52-Week Range | 1,010.00 - 1,356.20 |
| Beta | 0.09 |
| RSI | 64.81 |
| Earnings Date | Nov 5, 2025 |
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretrovira... [Read more]
Financial Performance
In 2024, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.
Financial StatementsNews
Aurobindo Pharma receives US FDA clearance for Unit-I; Warning letter officially closed
Aurobindo Pharma has received a significant regulatory boost with the United States Food and Drug Administration (US FDA) formally closing...
[Brokerage calls] Top stocks to watch on November 7: Cummins, UPL, Lupin, Aurobindo Pharma among key brokerage picks
Brokerage activity remained high on November 7, with major global firms including Nomura, CLSA, Morgan Stanley, HSBC, and DAM Capital...
Aurobindo Pharma Ltd (BOM:524804) Q2 2026 Earnings Call Highlights: Strong European Growth and ...
Aurobindo Pharma Ltd (BOM:524804) Q2 2026 Earnings Call Highlights: Strong European Growth and Strategic Pipeline Developments
Q2 2026 Aurobindo Pharma Ltd Earnings Call Transcript
Q2 2026 Aurobindo Pharma Ltd Earnings Call Transcript
Top stocks to watch today, November 6: TCS, Paytm, M&M, RBL Bank, Britannia Industries, Aurobindo Pharma and more
Indian stock markets are set for an eventful session on Thursday, November 6, 2025, as several heavyweight companies announced their...
Top Q2 results today, November 5: Aurobindo Pharma, Blue Star, Delhivery, Zydus Wellness more to announce earnings
The corporate earnings season for the July–September quarter (Q2 FY2025–26) continues in full swing, with more than 100 listed companies...
Aurobindo Pharma shares rise as US FDA concludes issues at Hetero Labs’ Vishakhapatnam warehouse
Shares of Aurobindo Pharma Ltd gained 1.15% to ₹1,097.50 in Monday’s early trade amid heightened scrutiny in the Indian pharmaceutical...
Aurobindo Pharma expands global footprint, incorporates new subsidiary in Chile to strengthen Latin American presence
Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary in Chile, marking another step in its...
Why are Aurobindo Pharma shares falling over 2% today? Explained
Shares of Aurobindo Pharma slipped 1.50% to ₹1,080.50 on Friday, inching closer to a 2% decline, as the Indian pharmaceutical sector reeled under pressure following U.S. President Donald Trump’s annou...
Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector
Indian pharmaceutical stocks came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented pharmaceutical drug...
Indian pharma stocks in focus as Trump announces 100% tariff on branded drugs
Indian pharma shares such as Sun Pharma, Lupin, Dr. Reddy’s, Cipla, and Aurobindo Pharma are in focus after Donald Trump announced a 100% tariff on imported branded drugs, effective October 1, unless ...
Aurobindo Pharma reports fire incident at its Andhra Pradesh unit
Aurobindo Pharma on Friday informed exchanges that a minor fire broke out at its Unit IV facility of APL Healthcare Limited, located in the Naidupeta SEZ, Andhra Pradesh, on September 18, 2025, at aro...
Aurobindo Pharma’s CuraTeQ Biologics successfully completes Phase 3 study for denosumab biosimilar
Aurobindo Pharma Limited announced on Friday that its wholly owned subsidiary, CuraTeQ Biologics, has successfully completed a pivotal Phase 3 clinical trial of its denosumab biosimilar against Prolia...
Top stocks to watch today, September 18: TVS Motor, Biocon, Aurobindo Pharma, Bandhan Bank, Federal Bank and more
Indian stock markets are set for another action-packed session on Thursday, September 18, with several corporate developments expected to keep select stocks in focus. Here are the top companies likely...
Why are Aurobindo Pharma shares up 5% today? Know More
Shares of Aurobindo Pharma Ltd surged nearly 5% in early trade on Wednesday, hitting ₹1,089.20 on the NSE, making it one of the top gainers of the session. The rally comes amid reports of easing conce...
Top stocks to watch today, September 8: BHEL, NTPC Green, Adani Green, Aurobindo Pharma and more
The Indian stock market is expected to see stock-specific action today, September 8, with several companies in the spotlight after major announcements and regulatory updates over the weekend. Here’s a...
Aurobindo Pharma’s Unit-XII receives US FDA Form 483 with 8 observations
Aurobindo Pharma Limited, one of India’s leading pharmaceutical companies, recently underwent a routine inspection by the United States Food and Drug Administration (US FDA) at its Unit-XII facility i...
Aurobindo Pharma’s CuraTeQ Biologics secures UK MHRA approval for biosimilar Dazublys
Aurobindo Pharma Limited announced that its step-down subsidiary, CuraTeQ Biologics s.r.o., has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA...
Aurobindo Pharma denies media reports on $5.5 billion Zentiva buyout
Aurobindo Pharma Limited has issued an official clarification regarding media reports suggesting that the company is closing in on a potential $5.5 billion acquisition of Zentiva. The clarification, f...
Pharma sector stocks in focus: Citi flags competitive setback for Dr Reddy’s, Aurobindo in iron sucrose opportunity
Citi has highlighted a potential setback for Indian generic drugmakers Dr Reddy’s Laboratories and Aurobindo Pharma after the USFDA approved two generic versions of Iron Sucrose, developed by Viatris ...
Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt
Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock declines. Gokaldas Exports saw the steepest fall at 15.9%, with other text...
Aurobindo Pharma share: Macquarie downgrades to underperform, flags US business concerns
Macquarie has retained an ‘Underperform’ rating on Aurobindo Pharma with a target price of ₹1,010, citing a weak Q1FY26 performance and rising concerns over growth in the US market. The stock currentl...
Aurobindo Pharma board declares interim dividend of Rs 4 per share for FY26
Aurobindo Pharma has announced a significant interim dividend of 400%, translating to ₹4.00 per equity share of face value ₹1 each. The decision was approved during the Board of Directors meeting held...
Top Q1 results today, August 4: Shree Cements, Aurobindo Pharma, DLF, Marico, Godfrey Phillips and more to announce earnings
A busy earnings day is lined up for Monday, August 4, 2025, with over 190 listed companies scheduled to release their financial results for the first quarter of FY26. The announcements span across mul...
Amid Trump tariff fears, Aurobindo strikes biggest deal; To acquire Lannett for Rs 2185 crore
Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is making its largest acquisitio.